Nanocarrier mediated drug delivery as an impeccable therapeutic approach against Alzheimer’s disease
2022
Taliyan, Rajeev | Kakoty, Violina | Sarathlal, K.C. | Kharavtekar, Sanskruti Santosh | Karennanavar, Chandrashekar R. | Choudhary, Yogendra Kumar | Singhvi, Gautam | Riadi, Yassine | Dube, Sunīla Kumāra | Kesharwani, Prashant
For the past several years, dementia, is one of the predominantly observed groups of symptoms in a geriatric population. Alzheimer’s disease (AD) is a progressive memory related neurodegenerative disease, for which the current Food and drug administration approved therapeutics are only meant for a symptomatic management rather than targeting the root cause of AD. These therapeutics belong to two classes, Acetylcholine Esterase inhibitors and N-methyl D-aspartate antagonist. Furthermore, to facilitate neuroprotective action in AD, the drugs are majorly expected to reach the specific target area in the brain for the desired efficacy. Thus, there is a huge requirement for drug discovery and development for facilitating the entry of drugs more in brain to exert a specific action. The very first line of defense and the major limitation for the entry of drugs into the brain is the Blood Brain Barrier, followed by Blood-Cerebrospinal Fluid Barrier. More than a barrier, these mainly act as selectively permeable membranes, which allows entry of specific molecules into the brain. Furthermore, specific enzymes result in the degradation of xenobiotics. All these mechanisms pose as hurdles in the way of effective drug delivery in the brain. Thus, novel techniques need to be harbored for the facilitation of the delivery of such drugs into the brain. Nanocarriers are advantageous for facilitating the specific targeted drug treatment in AD. As nanomedicines are one of the novels and most useful approaches for AD, thus the present review mainly focuses on understanding the advanced use of nanocarriers for targeted drug delivery in the management of AD.
显示更多 [+] 显示较少 [-]